Skip to content

Observational Study on cough syrup

Assessment of Efficacy, Safety and Tolerability of therapy with fixed dose combination (FDC) of Cetirizine with Ambroxol and Ambroxol as monotherapy in the treatment of productive Cough: An Open-label, Prospective, Multi-centre, Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2015/09/006198
Enrollment
250
Registered
2015-09-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- productive cough (cough with expectoration) associated with any of the nasal symptoms (nasal discharge,nasal stuffiness, nasal itching, and Sneezing) since at least previous 8 hours

Interventions

Intervention1: Relent Plus syrup by Dr Reddys: Ambroxol+cetrizine Control Intervention1: Mucolite syrup by Dr Reddys: Ambroxol

Sponsors

Dr Reddys laboratories Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children between over 6 to 18 years of age 2. Male and female children 3. Children having productive cough (cough with expectoration) associated with any of the nasal symptoms (nasal discharge, nasal stuffiness, nasal itching, and Sneezing) since at least previous 8 hours 4. Child willing to provide assent and parents/guardian willing to provide written informed consent 5. Willing and able to understand and comply with all study requirements

Exclusion criteria

Exclusion criteria: 1. Use of any throat lozenge, throat spray, cough drop, menthol-containing product, or any product with demulcent properties within last 8 hours 2. Use of any "cold medication" (e.g. nasal or systemic decongestants, antihistamine, expectorant, anti-tussive) within last 8 hours 3. Severe cough requiring hospitalization 4. Presence of fever within last 8 hours 5. Active pulmonary disease such as bronchopneumonia, bronchial asthma or tuberculosis 6. Known allergy to and/or hypersensitivity to ambroxol and/or cetirizine 7. Any other condition, which in the opinion of the clinician/investigator, could interfere significantly with the treatment and assessment process 8. Use of any investigational therapy within 30 days prior to randomization 9. Child not willing to provide assent and parents/guardian not willing to provide written informed consent

Design outcomes

Primary

MeasureTime frame
1. Total Symptom Score (TSS) for cough would be sum total of four scores given below: o Sputum volume, o Sputum viscosity, o Difficulty of expectoration, and o Severity of cough All above symptoms would be assessed on a 4-point scaleTimepoint: 1) 3rd day visit 2) 7th day visit

Secondary

MeasureTime frame
1. Total Nasal Symptom Score (TNSS) which is the sum total of scores for the following symptoms: o Nasal discharge, o Nasal stuffiness, o Nasal itching, and o Sneezing 2. Cough frequency (daily) assessed during follow-up visit 3. Number of awakenings in the night due to cough (24 hours) assessed during follow-up visit 4. Time taken for complete cough relief (days) assessed during follow-up visit Timepoint: 3rd Day 7th day

Countries

India

Contacts

Public ContactDr Sachin Aggrawal

Dr Reddys Laboratories Ltd

amitgarg@drreddys.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026